(Q38022320)

27 August 2017

title

Fulfilling the promise of rotavirus vaccines: how far have we come since licensure? (English)

1 reference

27 August 2017

1 reference

5

Umesh D Parashar

1 reference

27 August 2017

4

Jacqueline E Tate

1 reference

27 August 2017

2

Roger Glass

1 reference

27 August 2017

Manish M Patel

1

1 reference

27 August 2017

Rishi Desai

series ordinal

3

1 reference

27 August 2017

publication date

1 July 2012

1 reference

Lancet Infectious Diseases

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

561-570

1 reference

Global mortality associated with rotavirus disease among children in 2004.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Global Illness and Deaths Caused by Rotavirus Disease in Children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Performance of rotavirus vaccines in developed and developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Rotavirus vaccines: current prospects and future challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

GAVI enters its second decade with massive funding gap

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Real-world impact of rotavirus vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Sustained Decline in Cases of Rotavirus Gastroenteritis Presenting to the Childrenʼs Hospital of Philadelphia in the New Rotavirus Vaccine Era

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Change in rotavirus epidemiology in northeast Florida after the introduction of rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

The effect of rotavirus immunization on rotavirus gastroenteritis hospitalization rates in military dependents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Diarrhea-associated hospitalizations among US children over 2 rotavirus seasons after vaccine introduction.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Impact of rotavirus vaccination on hospital-acquired rotavirus gastroenteritis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Pentavalent Rotavirus Vaccine and Prevention of Gastroenteritis Hospitalizations in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Rotavirus vaccines in Belgium: policy and impact

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Trends in hospitalizations from all-cause gastroenteritis in children younger than 5 years of age in Brazil before and after human rotavirus vaccine introduction, 1998-2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Impact of rotavirus vaccination on diarrhea-related hospitalizations among children < 5 years of age in Mexico.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Reduction of diarrhea-associated hospitalizations among children aged < 5 Years in Panama following the introduction of rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Effectiveness of pentavalent rotavirus vaccine against severe disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Effectiveness of rotavirus vaccines for prevention of rotavirus gastroenteritis-associated hospitalizations in Israel: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Effectiveness of rotavirus vaccination in Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: The IVANHOE study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Effectiveness of Monovalent Rotavirus Vaccine (Rotarix) against Severe Diarrhea Caused by Serotypically Unrelated G2P[4] Strains in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Rotavirus in Asia: the value of surveillance for informing decisions about the introduction of new vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Oral rotavirus vaccines: how well will they work where they are needed most?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Incidence of severe rotavirus diarrhea in New Delhi, India, and G and P types of the infecting rotavirus strains

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Effect of rotavirus vaccination on death from childhood diarrhea in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Rotavirus strain types circulating in Africa: Review of studies published during 1997-2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Burden and typing of rotavirus group A in Latin America and the Caribbean: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Epidemiological profile of rotaviral infection in India: challenges for the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Human rotavirus vaccines: too early for the strain to tell

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix® and RotaTeq®, into the National Immunization Program of Australia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Molecular epidemiology of group A rotavirus in Buenos Aires, Argentina 2004-2007: reemergence of G2P[4] and emergence of G9P[8] strains.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Rotavirus P[4]G2 in a vaccinated population, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Intussusception among infants given an oral rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Ten years of the Global Alliance for Vaccines and Immunisation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

GAVI funding meeting exceeds expectations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Introducing new vaccines into developing countries: obstacles, opportunities and complexities

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Progress in the introduction of the rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Estimated research and development costs of rotavirus vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

Inactivated rotavirus vaccines: a priority for accelerated vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970029-4

7 January 2021

10.1016/S1473-3099(12)70029-4

Identifiers

DOI

1 reference

27 August 2017

1 reference